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The significance of the enterochromaffin-like (ECL) cell as a critical endocrine regulator of
gastric fundic mucosal function has only recently been recognized. Although the percentage of
these cells present in the human fundic mucosa is less than that in rodents, the observation that
they secrete histamine and are probably important modulators of parietal cell function has
resulted in their attaining some considerable biological significance. The further identification
ofgastrin and somatostatin receptors on the surface of the ECL cells has suggested that other
neurohormonal influences maybe significant in the regulation ofparietal cell function, utilizing
the ECL cell as an intermediate modifier. While abnormalities of ECL cells in the human
stomach (hyperplasia/neoplasia) have been mostly confined to observations in patients with
pernicious anemiaand atrophicgastritis, the recent recognition ofhyperplasia inpharmocother-
apeutically induced achlorhydric or hypochlorhydric states has excited considerable interest. It
has been proposed that the generation of luminal hypo- or achlorhydria by powerful acid
inhibitory pharmacotherapy may result in hypergastrinemia. This condition is responsible
initially for the development of hyperplasia and, subsequently, possibly even neoplasia of the
ECL system of the fundic mucosa. This phenomenon seems to be prevalent in rodents but has
so far been only rarely observed in humans, e.g., pernicious anemia, atrophic gastritis. In
particular, patients with the gastrinoma component ofthe multiple endocrine neoplasia type I
syndrome exhibit ECL-cell hyperplasia and neoplasia after exposure to acid inhibitory pharma-
cotherapy. It is therefore likely that an underlying genomic phenomenon is necessary prior to
the induction of hyperplasia and subsequent neoplastic transformation. The scientific evalua-
tion ofthe relationship between gastrin, ECL-cellfunction, and the development ofhyperplasia
and neoplasia may provide some important information in regard to the molecular evolution of
gastrointestinal neuroendocrine disease states. It is possible that the future pharmacotherapy
of acid secretory disease may require regulation not only of parietal cell but of ECL-cell
function.
INTRODUCTION
The possible relationship of the enterochromaffin-like (ECL) cells to gastric
pathobiology has recently generated considerable interest since the recognition of a
relationship between gastric carcinoidosis and hypochlorhydric states. It is probable
that ECL cells play a major role in the regulation of parietal cell function, and it
seems likely that ECL cells, in addition, exhibit a trophic regulatory function on the
gastric mucosa.
Of particular interest is the observation that pharmacotherapeutic agents which
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are associated with profound and sustained acid inhibition may have a role in the
generation ofECL-cell hyperplasia. Thisphenomenon has alsobeen noted in human
disease states in which a significant decrease in acid secretion is evident, namely,
chronic atrophic gastritis type A (CAG/A), with orwithout pernicious anemia (PA).
Offurther significance is the observation that patientswithgastrinomas andmultiple
endocrine neoplasiatype 1 (MEN-1) alsoexhibitECL-cell hyperplasia andneoplasia
(gastric carcinoid or ECLoma) after the induction of profound and sustained
inhibition of acid secretion with proton pump inhibitors. The likelihood ofa genetic
component in the genesis of human gastric neuroendocrine disease is therefore
probable.
HISTORY
The first description ofpeptide hormone-producing endocrine cells in the gastric
mucosa was in 1870, by Heidenheim, who described chromaffin cells in the dog
gastric mucosa [1]. In 1907, Ciacco introduced the term "enterochromaffin" (EC)
cells [2]. The endocrine nature of the EC cells, and their difference from adrenal
chromaffin cells, was first recognized in 1914 by Masson, who utilized silver impreg-
nation to demonstrate their argentaffin characteristics (capacity to generate and
accumulate metallic silver precipitates by reducing silver nitrate solution). Erspamer
and Asero, in 1952, identified 5-hydroxytryptamine (5-HT) as the endogenous
substance in the argentaffin (chromaffin) cells which reduced silver and chromium
[3].
Kull, in 1913, noted that the gastrointestinal tract contained cells with a morphol-
ogysimilar to that ofchromaffincells,whichwere unable to reduce silver nitrate (i.e.,
lacked argentaffinity). These cells were originally thought to be progenitors of the
EC cells. Dawson, in 1948, was the first to develop a method ofstaining these gastric
non-EC cells, utilizing a silver nitrate solution together with exogenous reducing
agents. This technique stained EC cells and many other endocrine cells [4] and
reflects the ability ofsecretory granules to accumulate and retain the resulting silver
precipitates (argyrophilia).
In 1966, Hakanson and Owan identified cells in the rat oxyntic mucosa that were
capable, like EC cells, of amine precursor uptake and decarboxylation [5]. In 1967,
they further reported that these cells were identical to histamine-containing cells of
the oxyntic mucosa [6,7] and introduced the term "enterochromaffin-like" (ECL)
cell. Capella et al., in 1969, reserved the term "enterochromaffin-like" for a distinct
oxyntic endocrine cell type identified by the characteristic electron microscopic
appearance ofits individual secretorygranules [8].
MORPHOLOGY-BIOLOGY
Seven different endocrine cell types and their respective secretory products have
been identified in the human stomach: the enterochromaffin (EC), somatostatin (D),
P/Dl, A (fetus and newborn), X, gastrin (G), and ECL cells. Gastrin (G)-secreting
cells are limited to antral mucosa, with the remainder predominantly distributed in
the oxyntic mucosa [9]. In gastric biopsies from ten healthy volunteers (five males,
five females), endocrine cells accounted for approximately 1.2 percent of the
epithelial volume and 0.9 percent of the mucosal volume [10]. By electron micros-
copy criteria, ECL cells account for 30-35 percent of the endocrine cell mass of the
oxyntic mucosa [10,11], a value which is substantially higher than that reported
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TABLE 1
Relative Frequency ofDifferent Endocrine Cells in Oxyntic Mucosa
ofRat and Man
Percentage ofTotal Endocrine Cell Mass
Cell Type Rat Man Mana
ECL cells 65 35 30
EC cells 0 25 7
D cells 10 26 22
P cells 24
D1cells 24b 14b 9
X cells 0.6
aMorphometry performed by electron microscopy (others by light
microscopy)
bCombined percentage ofP + D1 + X
Data from [1,2,6]
utilizing light microscopy (4 percent) [12]. D'Adda and Bordi noted that P and D
cells accounted for approximately 24 percent and 22-26 percent of the endocrine
cells inthe same region, respectively. There is some disagreement as towhether ECL
cells represent themajorityofthe endocrine cellpopulation ofthe fundus [13]. Inthe
rat, endocrine cells represent ± 2 percent of the normal oxyntic mucosa [14], and
ECLcells account for 65 percent ofthis population [15] (Table 1).
Identification and classification ofthegastric neuroendcrine cells have been based
largelyonthe different staining characteristics and theultrastructural morphologyof
their secretory granules, as determined by electron microscopy [9]. ECL cells are
argyrophilic, stain positively with Grimelius and Sevier-Munger techniques, but
negativelywith Hellerstrom-Hellman and Masson stains [9]. These cells lack demon-
strable monoamines and therefore are non-argentaffin (with the exception ofthe cat
and the rabbit [16]).
At the light microscopic level, human ECLcells are small, irregularly shaped cells
with pale cytoplasm and nuclei with fine nuclear membranes and chromatin [17].
Ultrastructurally, theyexhibit eithervesiculargranuleswith an irregular argyrophilic
core eccentrically located in awide space, or a round, relatively compact (orcoarsely
granular) argyrophilic core surrounded by a membrane of wavy appearance and
forming a thin clear space [9].
ECL cells are scattered in oxyntic glands, especially in the deep and intermediate
regions. No ECL cells have been identified in the gastric pits or in the epithelium
covering the luminal surface, and very few are present in the neck region. The cells
lack contact with the lumen ofthe gland, thereby forming a "closed configuration,"
and thus do not appear tobe influenced directlybyluminalgastricsecretions [9]. The
possibility of dendritic protrusions accessing the luminal surface has not been
excluded.
The exact function andprecise peptide/amine content ofthe human ECLcells has
not been completely determined. To date, a number of putative agents have been
proposed to occur in human ECL cells. As in other mammals, histamine has been
detected, but the number ofhistamine-storing granules in human ECL cells appears
to be moderate or low [16], as evaluated by the relatively low histidine decarboxylase
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activity identified [18]. The secretory granules ofthe ECL cell contain chromogranin
A, which appears to be involved in the mechanism of amine storage and silver
binding [19]. Human ECL cells, in addition, have been reported to exhibit immuno-
reactivity forboth the alpha subunit ofchorionicgonadotropin and calbindin [20,21].
Gastrin and somatostatin receptors have been identified on rodent (mastomys) ECL
cells [22] and may therefore exist in the human ECL-cell system. Somatostatin
receptors have been identified on the cells ofhuman carcinoid samples [23].
A putative role for calcium in the secretory regulation and pathobiology of ECL
cells has been proposed, but the details remain controversial. Calbindin, a 28 kDa
calcium-binding protein, has been identified in ECL cells of lower mammalian
species and in human ECL cells [23,24]; however, the function is unclear. Calbindin
has been demonstrated in a number ofneuroendocrine cells, including: parathyroid
C cells, secretin- and enteroglucagon-containing cells, pancreatic glucagon/
insulin/PP cells, adrenal medullarycells, and enteric neurons [23,25]. It seems likely
that calbindin may be involved in mechanisms of calcium-mediated endocrine cell
secretion or in intra- or extracellular calcium homeostasis [23].
Antral gastrin has been postulated to influence calcium metabolism [26,27] by
release of gastrocalcin, a putative hypocalcemic peptide found in ECL cells of the
gastric fundus [28]. Gastrocalcin secreted by ECL cells, under gastrin stimulation,
may interact with calbindin in the gastric modulation ofcalcium homeostasis.
Overall, the ECL system requires to be better defined in terms of its cell biology
and molecular physiology. It is quite likely that a number of significant regulatory
peptides important in gastric secretion are present within this cell, and the elucida-
tionoftheir function maybe ofcritical concern inunderstanding mucosalbiology. Of
particular importance would be the identification of trophic regulatory peptides,
particularly the trefoil group, since the relationship between endocrine regulation of
mucosal growth and the development of neoplasia in a cell system of a different
phenotype maybe ofconsiderable pertinence.
ECL-CELL FUNCTION
The previous concept of the regulation of acid secretion held that gastrin was a
primary modulator ofparietal cell function. In addition, histamine was hypothesized
to play an important role in acid secretion, alsovia a direct effect on the parietal cell.
The source of histamine was controversial. Initially, mast cells and, more recently,
ECL cells were proposed as putative sources. The vagus was felt to modulate acid
secretion via the effect of acetylcholine on the parietal cell. Receptors for all three
chemical messengers had been identified on the parietal cell, and their presence was
consistent with a triumvirate modulation of acid secretion. The dominant inhibitory
effect ofH2-receptor blockade suggested that histamine was the prime modulator of
acid secretion. More recently, the three-receptor model of acid secretion has been
reevaluated, and the ECL cell has assumed a more dominant role. Current under-
standing would indicate that gastrin primarily drives the ECL cell to generate
histamine, which is the dominant activatorofparietal cell acid secretion (Fig. 1). This
scenario is consistent with experimental observations that, in the isolated parietal
cell system, gastrin alone is a poor stimulant of parietal cell function. Conversely,
histamine alone is a powerful agonist of acid secretion, and the addition of gastrin
results in only a mild augmentation of acid secretion. Similarly, states of hypergas-
trinemia result in substantial hyperplasia of ECL cells and augmented levels of
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FIG. 1. The ECL cell occupies a central regulatory role in the modulation of parietal cell secretion.
Gastrin is responsible for stimulating histamine secretion from the parietal cell, which generates acid
production. It is probable that gastrin exerts a trophic effect on both ECL cells and gastric gland stem
cells. The exact role of neural regulation and the interaction with somatostatin remains to be defined
precisely. Hydrogen protons themselves exert a modulatory role on gastrin secretion.
histamine production. The role of the vagus and acetylcholine seems to be less
substantial but of some importance. In essence, the ECL cell may be the major local
regulator of parietal cell function and, in addition, subserve an as yet poorly
identified role in the trophic regulation ofgastric fundic cell lineage.
DEVELOPMENTAL AND AGE-RELATED CHANGES
IN HUMAN ECL-CELL POPULATIONS
The origin ofneuroendocrine cells and, in particular, ECL cells is still disputed-
with endodermal or neuroectodermal origin debated. Endocrine cells first appear in
fetal development in the ninth to tenth week. Enterochromaffin (EC) and somato-
statin D cells mature first, and fundic ECL cells appear later, at approximately 14
weeks [9]. Few studies have addressed the question ofECL-cell changeswith age/sex
or during development. In general, neuroendocrine cells have been reported to
decrease with advancing age [29], but Stachura et al. in 1987 noted that, in the rat,
the number of ECL cells increased with age [30]. Human data indicates that
ECL-cell density declines with age in males, whereas, in females, no significant
difference in cell density between young and old was evident [31]. Older females
exhibited a higher rate of asymptomatic gastritis with associated increased levels of
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gastrin and ECL-cell number. This findingwas interpreted as evidence ofthe trophic
effect ofgastrin on ECL cells [31,32].
The situation as regards the regulation ofECL-cell growth and proliferation is not
definitely understood. Clearly the relationship of an endocrine cell system which
changes with age is important in an organ where the genesis of neoplasia is not
understood, and it appears related to alterations in acid secretion and mucosal
turnover that occur with age. The specific local and distant regulatory factors of
ECL-cell proliferation require identification.
ECL PATHOBIOLOGY IN HUMAN DISEASE PROCESSES
Although the cellular mechanism of ECL-cell function is poorly understood, its
involvement in several pathophysiological states is evident. ECL-cell pathology has
been reported in human diseases predominantly associated with trophic effects of
hypergastrinemia. Such conditions may occur secondary to tumor (gastrinoma with
or without MEN-1), or low acid secretory states (e.g., chronic atrophic gastritis type
A), pernicious anemia, or peptic ulcer management associated with prolonged and
profound acid inhibition bypharmacological or surgical interventions.
Gastric endocrine tumors (carcinoids) account for approximately 3 percent of all
gastrointestinal carcinoids [33,34], but only 0.3 percent ofall gastric neoplasms [35].
More recently, Solcia et al. reported that gastric carcinoids account for up to 30
percent of all carcinoids in the gastrointestinal tract and suggested that this fact may
reflect the introduction ofimproved diagnostic techniques [36]. In the same series, 41
out of 46 endocrine growths were identified in the oxyntic mucosa. Most gastric
argyrophilic carcinoids investigated ultrastructurally have proved to be ECL tumors
or to contain a predominant ECL-cell component [37]. Pure or mixed "ECLomas"
account for 63 to 84 percent of all gastric endocrine tumors found in CAG/A and
gastrinoma with or without MEN-1 [36,38]. Rogers and Murphy, in 1979, reported
that 7 percent of routinely diagnosed gastric malignancies, previously classified as
adenocarcinoma, were carcinoids ormixed tumors [39].
The delineation ofthe precise morphology ofneuroendocrine malignancies ofthe
gastrointestinal tract is difficult. Lightmicroscopy and immunocytochemistryprovide
a morphological description of a tumor, but fail to define either its lineage, biological
behavior, or even the potential for alteration of phenotype. Considerable difficulty
has been experienced in the identification of the change from hyperplasia to
neoplasia. A number of different markers of both nuclear and cytoplasmic domains
have been suggested as providing criteria for identification of the change to neopla-
sia; these are dealt with by Solcia et al. elsewhere in this symposium. A particular
issue is the exact cell type involved and the issue of whether cell phenotype may
change at a particular level of hyperplasia. Thus the identification of a neoplasm
which has progressed from ECL-cell hyperplasia to either a pure ECLoma or to an
ECLoma which exhibits EC cells is an important issue. In general, it is felt that
ECLomas follow a benign course, whereas tumors which are mixed or contain EC
cells behave in a far more malignant and unpredictable fashion.
Peptic UlcerManagementandECL-CellPathobiology
Recent surveys have estimated the annual incidence of chronic duodenal and
gastric ulceration to be ten to 20 per 1,000 adult population. Alifetime prevalence of
chronicpeptic ulcer disease approaches 10 percent ofthe population [40].
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Asignificant number ofpatientsmayrequireprolonged and profound suppression
of acid secretion, especially in the management of chronic peptic ulcers orreflux
esophagitis. Maintenance therapy to prevent recurrence may extend over many
years. Acid suppression may also be required in patients who have undergone
vagotomy with or without resection of the gastrin-secreting antrum. In clinical
experience, H2-receptor blockers, vagotomy, and the use of omeprazole have been
reported to result in acutely increased levels of circulating gastrin [41-44], but a
consistent effect on ECL-cell hyperplasia was not demonstrated.
The potential risk of developing gastric carcinoid/carcinoma with prolonged
pharmacologic suppression of acid secretion was initially raised in 1979 by Elder et
al. [45]. Hawker, in 1980, also reported gastric carcinomas in patients receiving
cimetidine forbenigngastriculcers, confirmed bynegative endoscopic biopsies ofthe
stomach [46]. In 1983, Colin-Jones et al. reported a surveillance study of 9,928
patients treated with cimetidine versus age- and sex-matched controls. In this study,
gastric carcinoma was found in 74 cimetidine-treated patients versus eight in the
controlgroup; however, in themajority ofthe 74 in the treated group, the occurrence
ofgastric carcinoma could not be attributed to cimetidine therapy (23 carcinomas
diagnosed before treatment; 29 had advanced malignant tumor with less than six
months' treatment) [47]. A large study from Copenhagen, of 17,000 patients on
cimetidine, demonstrated a tenfold increased riskofdeveloping gastric cancerversus
controls, but also noted that the risk declined with age in conjunction with the
declining risk of other malignancies studied in this cohort [48]. The newer, more
potent competitive H2-receptor blockers, such as ranitidine and famotidine, and the
H-K ATPase blocker, omeprazole, have not been utilized for a sufficient time in a
clinical setting to draw any firm conclusions regarding their effect on the pathogene-
sis ofgastric carcinoma/carcinoid.
Quantitative studies of patients on omeprazole (20 to 60 mg/day) for resistant
peptic ulcerdisease/refluxesophagitis for aperiod ofup to three years have noted an
increase in circulating gastrin levels (from 81.5 to 206 pg/ml in one study). No
significant hyperplasia of gastric endocrine cells, especially ECL cells, was noted,
however, nor was there evidence of dysplasia or neoplasia [49-51]. Solcia et al.
reported mild hyperplasia in only 11 to 19 percent of patients on long-term
omeprazole (meanperiod oftreatment was 13 months). This result was attributed to
associated atrophic gastritis present. The focal changes were unrelated to gastrin
levels orlength ofomeprazole treatment [52]. Conversely, however, Bordi et al. have
reported that, although the entire endocrine population of the oxyntic mucosa
remains unchanged following omeprazole, the mean volume fraction of ECL cells
was increased by 64 percent as compared with normal values. They also noted that
thegranule content in the ECL cells was lower than comparable normal values[53].
It is noteworthy that, in the large cohort studies on cimetidine, endocrine cell
hyperplasia and carcinoids have not been documented.
While cautious evaluation continues in regard to the role of acid-suppressing
agents in thebiology ofgastric adenocarcinoma, the evaluation of experimental data
in animal studies has revealed an increased incidence of gastric carcinoids when
treatedwithagentswhich both inhibit acid and are associated with hypergastrinemia.
It appears that significant acid inhibition and prolonged periods of therapy seem
necessary to generate such lesions [14,54-58]. An increased predilection in female
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animals has been noted, suggesting either a hormonal or genetic influence on the
evolution of ECL pathology.
Therelationship betweenpeptic ulcerdisease and ECL-cell pathobiology is clearly
an area ofconsiderableimportance. It is asyet notclearwhether ECL-cell function is
altered due to the peptic ulcer disease itself or, alternatively, reflects changes
initiated by the use of acid inhibitorytherapy. A studywhich addresses this question
wouldprovide important information. As the situation currently stands, the relation-
ship ofECL-cellproliferation topeptic ulcer disease and itsmanagement needs to be
monitored carefully on an ongoing basis.
ChronicAtrophic Gastritis and PemiciousAnemia
ECL-cell pathobiology in animal models has been well characterized [59] but has
only been studied in detail in two human pathological conditions: gastrinoma (see
below) and chronicatrophicgastritistype A(CAG/A). Both these conditions exhibit
a diffuse qualitative and quantitative oxyntic argyrophilic cell hyperplasia.
CAG/A is characterized by chronic inflammation of the oxyntic mucosa, often
autoimmune, resulting in progressive atrophy of oxyntic glands and achlorhydria.
The antral mucosa is unaffected by the inflammatory changes, and gastrin G cells
(with no negative feedback by acid, due to the achlorhydria) generate hypergas-
trinemia and secondary fundic mucosal ECL-cell hyperplasia. CAG/A is a common
finding in autoimmunepernicious anemia, butmay exist independently [60].
Bordi, Solcia et al. have described in detail the qualitative relationship between
hypergastrinemia andoxynticargyrophilic cell hyperplasia, detailing the histological
pattern, and haveproposed a classification for this hyperplasia [9,61,62]. In Western
countries, post-atrophic gastritis carcinoid tumors may account for up to 43 percent
of gastric carcinoids, of which 63 percent are usually associated with pernicious
anemia [63]. Ofinterest is the observation that the prevalence ofgastric carcinoids in
pernicious anemia without CAG is 1.2-8 percent [64]. In a survey of 55 cases (from
three studies) of CAG-related gastric carcinoids, all were found in the fundus, and
qualitatively most constituted ECL cells [63]. Forty-two percent of these ECLomas
were noted to be multiple, 18 percent exhibited hepatic metastases, but none were
associated with the carcinoid syndrome. Aprimary observation of this study was the
association of the gastric carcinoid lesions with massive hypergastrinemia of antral
G-cellorigin: 15 to 57 times theupper limit ofnormal[63]. The survey also noted that
the age ofpatients with gastric carcinoids secondary to CAG appeared lower than
theage ofCAGpatients withhyperplasia alone (no tumor) and that the gastrin levels
were significantly higher in the tumor patients versus the hyperplasia group [63].
Some ECLomas have been reported to regress following antrectomy, with subse-
quent normalization ofgastrin levels [65-68].
The mucosal histamine content in CAG has been found to be increased and
significantly correlated to the number ofargyrophilic ECL cells [69]. The functional
significance of histamine associated with ECL-cell hyperplasia in humans is still
unclear, but sustained local release of histamine may contribute to excessive acid
hypersecretion associated withgastrinoma. Thus the likelihood of histamine playing
asignificant role in the evolution ofthe fundic hypersecretory state in patients with
gastrinoma may reflect a local augmented release of histamine. In support of this
hypothesis is the fact that significant ECL-cell hyperplasia has been noted in the
fundic mucosa of patients with Zollinger-Ellison syndrome [70]. Of particular
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relevance, however, is the recent observation that histamine itself may exert mito-
genic effects. Further support of this observation in the stomach is born out by the
inhibition of ECL-cell hyperplasia engendered by hypergastrinemia when the ani-
mals are exposed to a histamine 1 receptor blocker. It is therefore possible that
histamine may function not only as a secretory agent in the fundic mucosa but also
participate in a feedback inhibition loop within the ECL system responsible for
trophic regulation.
Zollinger-Ellison Syndrome (Gastrinoma) andMultipleEndocrineNeoplasia
Zollinger-Ellison syndrome (ZES) provides a useful model to evaluate the effects
of chronic hypergastrinemia on human oxyntic endocrine cells [70]. The association
between ZES and hyperplasia ofthese cellswas initiallyrecognizedby Bordi et al. in
1974 [70]. Morphometry ofgastric endocrine cells in patients with ZES has revealed
that the volume density of endocrine cells is approximately 3.2 percent of the
mucosal epithelial component-a 168 percent increase over normal subjects. In the
ZES group, ECLcellscomprised greater than 50 percent ofthe entire endocrine cell
mass. The mean volume fraction of the ECL cell in ZES was 65 percent-a 119
percent increase over normal controls [71]. The majority ofpatients with ZES have
low-grade ECL-cell hyperplasia, whereas those with MEN-1 exhibit high-grade
(linear-micronodular) hyperplasia or carcinoid tumors. Thus, 15 ZES patients-six
of eight with MEN-1 compared with only four of nine without MEN-1-demon-
strated high-grade hyperplasia "precarcinoid" [36,72].
Interest in MEN-1 relates to the underlying genetic predisposition of such
individuals to develop endocrine tumors, including gastric carcinoid. The MEN-1
gene has been identified on chromosome 11, and it is probable that clinical MEN-1
results from two mutational events affecting the MEN-1 locus, with the gene for
MEN-1 functioning as a growth suppressor in normal cells [73-75]. Two initiation
models demonstrate that an inherited tumor results from the unmasking of a
recessive gene at the disease locus [74]. The first mutation is carried in the germ line,
while the second mutation serves to eliminate the remaining wild-type allele at this
locus [74]. In MEN-1 patients with gastrinoma, it is possible that gastrin or some
other trophic factors increase the mitotic rate ofthe ECL cell and thereby exponen-
tially increase the probability of occurrence of the second mutational event. This
hypothesis is consistent with the higher incidence of argyrophil cell hyperplasia
elicited by hypergastrinemia in combined ZES/MEN-1 patients, compared to pa-
tients with ZES alone. Possible alternative trophic agents include fibroblast growth
factor (FGF), which hasbeen demonstrated inplasma ofMEN-1 patients and shown
to be mitogenic for parathyroid tissue [76,77]. A cooperative role between classic
growth factors and gastrin may exist in the genesis ofargyrophil cell lesions. Such an
interaction may be responsible for tumor promotion. The role of FGF as a mitogen
may be related to the positive association between gastric carcinoid and hyperpara-
thyroidism (in the absence of ZES or MEN) [78-80]. The relationship between
parathyroid hormone, ECL-cell function, and antral G cells requires further evalua-
tion [20,81].
While modern therapeutic strategy in ZES is directed toward the eradication of
the tumor process [82], only 60-80 percent of patients with duodenal wall gastrino-
mas and 15-20 percent ofpancreatic gastrinomas may be viable surgical candidates
[83]. Thus, in the majority, acid hypersecretion has been managed by either total
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gastrectomy or potent anti-secretory agents. Aconcern ofthe lattertherapyhasbeen
raised by the result of experimental animal studies, which have revealed major
increases in plasmagastrin levels and gastric carcinoid formation [54,57,84,85]. Lehy
et al. in 1989 demonstrated in a study of 22 ZES patients that 77 percent exhibited
argyrophil cell hyperplasia (versus normal controls), regardless of the acid-
suppressive agent used (ranitidine, omeprazole, SMS 201995, pirenzipine with or
without ranitidine) [86]. This result was similar to that reported by Bradram and
colleagues, who noted that 79 percent of ZES patients (15 of 19 cases) exhibited
argyrophil hyperplasia independent of the type of treatment (omprazole or raniti-
dine). These data were not compared with controls, and seven of the 19 cases
demonstrating hyperplasia were untreated ZES patients [87]. Bradram et al. in this
semiquantitative study demonstrated no significant difference in the degree of
hyperplasia between ZES patients with or without acid suppression treatment
(ranging between eight and 84 months) [87]. Helander, in a quantitative study of 14
ZES patients before and after 6-21 months ofomeprazole treatment, confirmed this
observation and reported no significant change in endocrine cell density over the
time course of treatment (on successive biopsies) [88]. Lehy et al. noted a positive
correlation between argyrophil cell density and duration of omeprazole treatment,
but indicated that seven often patients showed no significant increase in cell density
within the initial 18 months [86]. Both Bradram and Lehy reported a positive
correlation between the degree ofhyperplasia and the fastinggastrin level.
THE ROLE OF GASTRIN IN HUMAN ECL-CELL PATHOBIOLOGY
The role of gastrin in the pathogenesis of human gastric carcinoid formation has
been studied both in a clinical setting and in experimental animal models. Studies
have been based on two models: hypergastrinemia secondary to achlorhydria and
hypergastrinemia secondary togastrin-producing tumors. The former is associated in
humans with CAG with or without PA, whereas, in animal models, the effect has
been demonstrated using potent acid-suppressing agents, fundectomy, antral exclu-
sion, orportal systemic shunting.
Anumber ofinvestigators have demonstrated in humans that, in the hypochlorhy-
dric/achlorhydric conditions found in CAG/PA, serum gastrin levels are elevated
and correlate with endocrine cell (especially ECL-cell) hyperplasia and carcinoid
formation. In animal models, sustained and potent acid suppression has generated a
similar outcome. In several of these animal models, predominantly the rat, it has
been shown that eitherwithdrawal ofthe drug or antrectomy results in a normaliza-
tion ofhypergastrinemia and reversal of the hyperplastic/carcinoid state [56,65,89].
The second "model" which further defines the role of gastrin on the ECL-cell
population is the ZES/MEN-1 patient group. The ECL-cell hyperplasia associated
with ZES correlates with the serum gastrin level (see above), except in cases ofZES
associatedwith MEN-1, where an additional geneticfactor (agent) and nothypergas-
trinemia alone mayinteract in thegeneration ofa severe hyperplasia/carcinoid state.
This fact poses the question as to whether sustained hypergastrinemia alone is the
risk factor in the development ofgastric carcinoid tumors. Alternatively, associated
chemical regulators, growth factors, or genetic events need to be identified in order
to define the cellular mechanism of action by which the neoplastic process is
initiated.
Gastrin has at least two major biological effects: stimulation of gastric acid
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secretion and promotion ofgastric mucosal growth-in particular, the promotion of
self-replication of ECL cells [90-93]. The interaction between gastrin, ECL cells,
histamine, and parietal cells has been studied in an attempt to delineate regulatory
events in the histogenesis of the gastric mucosa. Two events appear of critical
importance. First, the effect ofgastrin on the ECL cell and parietal cell and, second,
the influence of gastrin on the release of histamine. A trophic role for histamine in
gastric mucosal histogenesis may also be a plausible alternative, since ECLcells in a
number of species, including man, produce histamine, which has known mitogenic
properties [16]. The direct action ofgastrin on parietalcells, as an acid secretagogue,
appears unlikely, and in numerous experimental preparations histamine is a more
efficient acid secretagogue [94]. Sandvik et al. have reported that gastrin produces
immediate and concentration-dependent histamine release in an isolated stomach
preparation. They also noted that gastrin-induced histamine release is sufficient to
explain the acid-stimulatory effect ofgastrin [95,96]. Thus, the general trophic effect
of gastrin on the gastric mucosa might either be direct or mediated via alternative
agents (PYY, enteroglucagon, or histamine) released from ECLcells.
Crean et al., in 1969, demonstrated a specific and marked trophic effect ofgastrin
on parietal cells in the rat [97]; however, since gastrin, at least in the rat, exerts its
effect by releasing histamine [96], maximal gastrin-stimulated acid secretion may not
only reflect parietal cell mass, but also the histamine-releasingcapacity ofECLcells.
In this review, the effect of endogenous hypergastrinemia on ECL-cell density has
been noted. Waldum et al. have extended these studies and reported that rats
treated for 90 days with omeprazole with or without astemizole not only exhibit a
serum gastrin increase, but also gastrin-stimulated histamine release. This histamine
release correlateswith the increase in ECL-cell density reported elsewhere [98].
Mastomys natalensis, an African rodent, is a useful model to study the role of
chromosomal abnormalities in gastric carcinoid formation, since this animal sponta-
neously produces gastric carcinoids in 16-24 months but, unlike ZES with MEN in
humans, does not naturally exhibit hypergastrinemia [99]. When hypergastrinemia is
induced by achlorhydria secondary to irreversible H2 blockade, however, gastric
carcinoids form in four to six months [58]. This species clearly provides evidence of a
genetic factor facilitating the effects ofhypergastrinemia.
Hypergastrinemia in non-antral atrophic gastritis was initially noted in 1970 by
Yalow and Berson and related to achlorhydria [100]. Endocrine cell proliferation in
the atrophic mucosa of such patients has been well described [62,63,101,102], with a
correlation demonstrated between serum gastrin levels and gastric carcinoid forma-
tion in patients with CAG [101].
Atrophicgastritis has been noted in patientswith peptic ulcer disease [101]. Solcia
et al. have reported that, in 122 patients with peptic ulcer disease, none had gross
hypergastrinemia, yet 19 percent ofpatients demonstrated ECL-cell hyperplasia (no
dysplasia/neoplasia was evident) [103]. This finding may suggest that dysplastic or
neoplastic lesions do not develop in areas ofatrophic gastritis unless gross hypergas-
trinemia exists for a number ofyears, as in pernicious anemia [64]. In experimental
reports, Solcia and Lundell both noted that antrectomy in patients with gastric
carcinoids secondary to PA resulted in complete regression of tumor and normaliza-
tion of serum gastrin levels [67,104]. This reversible process suggests that an
irreversible initiation event (e.g., genetic damage) may not be involved.
Acid suppression using either H2-receptor blockers or proton pump inhibitors
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causes a dose-dependent increase in gastrin levels in humans [104]. Omeprazole (40
mg/day) resulted in a rapid rise in serumgastrin from 81 pg/ml to 220pg/ml in two to
three months, with a constant level maintained over the next 37-56 months. A survey
of 241 patients on omeprazole, with regular monitoring by endoscopic biopsies and
serumgastrin levels, noted thefollowing: antrectomypatients exhibited a lowvolume
densityofargyrophilic cells in the oxyntic mucosa, and thevolume density inpatients
on 40 mg/day ofomeprazole increased slightly (just reaching a level ofsignificance)
in the first year, less markedly in the subsequent three years. Large variations
between individuals and evenwithin the same individual also existed [105]. No severe
hyperplasia was evident. A positive correlation between individual serum gastrin
levels and ECL-cell volume densities was noted.
The failure to correlate severe hyperplasia in long-term omeprazole treatment
with gastric carcinoids found in patientswith CAGwith orwithout PA, or carcinoids
found in animal models may be explained in two ways. First, endocrine cell
hyperplasia in humans progresses very slowly, as demonstrated by a serial gastric
biopsy study by Roucayrol and Cattan. In patients with CAG, serum gastrin slowly
increases over a mean period of five years [106]. Thus gastric carcinoids in PA may
take up to ten years or more to develop. A second explanation for the discrepancy
between omeprazole and CAG with PA patients and carcinoid outcome may reflect
the different levels of gastrin in the two patient groups. The latter exhibit a much
higher and more sustained level than that observed in those on omeprazole. This
suggestion has been evaluated in studies of 24-hour intragastric acidity and plasma
gastrin concentrations before and during treatment with ranitidine (2 x 150 mg/
day) or omeprazole (20 mg/day) versus patientswith PA. Median gastrin concentra-
tions in PA patients were approximately tenfold greater than in either treatment
group [107].
The current consensus is that high-dose therapy with omeprazole causes only
moderate hyperplasia in man, and prolonged treatment has not been shown to
increase further the gastrin level or to cause progression of the hyperplasia. Data
from MEN-1 and PA patients reviewed in conjunction with animal studies indicate
that a substantial level ofhypergastrinemia, with or without possible genetic predis-
position/initiation, may be a prominent mechanism in gastric carcinoid tumorigene-
SiS.
While it is likely that gastrin is a primary player in the relationship between
ECL-cell hyperplasia and neoplasia, it is probable that other agents are also
involved. The gastric mucosa is a major source of trefoil peptides, which themselves
are important regulators ofcell proliferation. Similarly, histamine has been reported
to exert mitogenic effects. Furthermore, the parietal cell itself is known to possess a
number ofagents with trophic activities, suggesting that a complex cascade involving
gastrin and a numberofotherchemical messengers are components ofthe regulation
ofthe ECL-cell cycle.
PHARMACOTHERAPY AND ECLOMAS
The pharmacotherapy of peptic ulcer disease and ZES has principally involved
methods of controlling acid secretion. Although peptic ulcer disease was first
described in the late eighteenth century, it was not until 1886 that hyperchlorhydria
was offered as the cause ofulcers [108]. Early approaches to treatment included diet
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modification and surgical intervention, such as gastric resection and truncal vagot-
omy.
The first pharmacological intervention involved the use of antacids to neutralize
the acid. Subsequently, anticholinergics were utilized to inhibit acid production. In
1976, the introduction of the H2 histamine receptor antagonist class of agents
established a significant advance in the treatment of peptic ulcer disease, reflux
esophagitis, and ZES. More potent and/or longer acting H2-receptor antagonists can
produce a profound and long-lasting suppression of intragastric acidity. The anti-
secretory effect of drugs such as loxtidine, SK94482, and sulfotidine extend over an
entire 24-hour dosing interval, unlike the short-term effects noted with more
commonly used H2 blockers (cimetidine, ranitidine, and nizatidine). This pattern is
similar to that exhibited by omeprazole-a proton pump inhibitor. Both loxtidine
and sulfotidine were withdrawn from clinical development subsequent to the devel-
opment of gastric carcinoids during animal studies. To date in the U.S.A., omepra-
zole is licensed by the FDA for acute treatment of severe gastro-esophageal reflux
disease unresponsive to antacids or H2 antagonist therapy and long-term usage in
erosive esophagitis and chronic treatment of ZES. The profound and sustained
inhibition of acid secretion by omeprazole results in achlorhydria in over 90 percent
of patients [109] and is associated with more rapid ulcer healing than ranitidine or
famotidine [110]. Based on the efficacy of the class of agents (substituted benzimid-
azoles), further agents oftheir type have been designed (e.g., lansoprazole [111] and
AG1749 [112]). Animal data demonstrating the correlation between lifelong hyper-
gastrinemia (secondary to acid suppression) and gastric carcinoid formation has not
been reconciled with the apparent lack of similar results in human studies
[54,57,84,85,91]. Overall, animal data indicate that substantial and/or prolonged
administration of any potent acid suppressor is associated with hypergastrinemia,
and the evolution ofacarcinogenic process. The majorissue in humans is that studies
utilizingsuch agents have notyetbeen evaluated overlongtime periods. It ispossible
that periods of 15 to 20yearsofexposure (constant orintermittent) maybe necessary
forvalid correlations to emerge.
Creutzfeldt and colleagues have proposed that, because ofthe critical importance
of hypergastrinemia in the scheme for development of gastric mucosal neoplasia,
monitoring of serum gastrin levels in patients undergoing long-term acid suppres-
sion, especially omeprazole, is advisable. In addition, gastric biopsies may also be
necessary in the management of such patients. They further suggested that serum
gastrin levels five times above the upper limit of normal may be an indication for
reduction ofthe omeprazole dose. For the present, however, neither a critical gastrin
concentration nor a maximum treatment period beyond two years has been estab-
lished. Longer observation periods and larger patient numbers are necessary to
define these limits [50].
The perspectives for new anti-secretory drugs with unique mechanisms of action
are being identified at present. Garner hasproposed the future use ofshort-acting or
reversible H-K ATPase inhibitors as well as hybrid molecules comprising a gastrin
antagonist linked to an unsurmountable H2 antagonist [113,114]. Clearly the role of
the ECL cell in the physiology ofacid secretion and in the pathobiology ofthe gastric
mucosa is only now becoming apparent. It is likely that the role of the gastric
neuroendocrine system may achieve critical importance in the future management of
gastric disease processes.
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